Advertisement
Michael Breen. PhD Director of Infectious Diseases and Ophthalmology at GlobalData comments: “That the US pays more for drugs than other countries is unquestionable and must be addressed. However addressing this in any meaningful way has invariably resulted in failure. This is a highly nuanced issue that involves multiple players; bringing everyone to the table and getting a result with which all parties are satisfied is a challenging proposition.
Advertisement
“Complicating Trump’s order further it is unclear exactly how and when it will be implemented. Considering that the timing of the announcement falls so close to an election raises concerns that the order is being rolled out for optics and influence with less emphasis on execution of the order and its overall impact.
“It is difficult to envision the pharma industry not pushing back against this with a rapid legal challenge. The legality of this order is unclear and impossible to predict given the lack of clarity surrounding its underpinnings. It is possible that this order will never become fully realized leaving little if any impact on the industry save for yet more unfulfilled promises to lower drug prices.”
